Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial

Akbar AliAsgarzadeh, Sanaz Karimiavval, Jalil Houshyar, Morteza Gojazadeh, Alireza Hadi
2020 Journal of Clinical and Diagnostic Research  
Although bromocriptine has been approved as an antidiabetic agent, few studies have reported the beneficial effects of other anti-hyperglycemic long acting dopamine agonist agents. In this regard, Cabergoline has fewer side-effects than that of Bromocriptine which can be administered as one or two days per week with higher compliance rates in patients. Aim: To determine the effect of Cabergoline on glycaemic control in patients with Type 2 Diabetes Mellitus (DM).
doi:10.7860/jcdr/2020/43034.13481 fatcat:q5zhfyzdjjhg7bjichttk2yvvm